Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting
2023 ESMO WCGIC Insights: "Updated Survival Analysis of the DEEPER Trial by JACCRO - Modified (m)-FOLFOXIRI + Cetuximab vs. m-FOLFOXIRI + Bev as Initial Treatment for RAS & BRAF wt-mCRC"
Login to view comments.
Click here to Login
